Discounted Cash Flow (DCF) Analysis Levered

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC (ADAP)

$4.84
0.04 (+0.83%)

Free Cash Flow

Year
A/P
Revenue
Revenue (%)
Operating Cash Flow
Operating Cash Flow (%)
Capital Expenditure
Capital Expenditure (%)
Free Cash Flow

Weighted Average Cost Of Capital

Share price $ 4.84
Beta 2.268
Diluted Shares Outstanding 629,805.22
Cost of Debt
Tax Rate -0.18
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 20.514
Total Debt 39.13
Total Equity 3,048,257.26
Total Capital 3,048,296.39
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
Revenue
Operating Cash Flow
Capital Expenditure
Free Cash Flow
WACC
PV LFCF
SUM PV LFCF

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -50.41
Equity Value -
Shares Outstanding 629,805.22
Equity Value Per Share -